| Primary |
| Urinary Tract Infection |
26.5% |
| Product Used For Unknown Indication |
11.1% |
| Cellulitis |
9.4% |
| Staphylococcal Infection |
9.4% |
| Infection |
7.4% |
| Drug Use For Unknown Indication |
5.4% |
| Sinusitis |
5.4% |
| Skin Infection |
3.4% |
| Prophylaxis |
3.0% |
| Bronchitis |
2.7% |
| Hypertension |
2.3% |
| Bacterial Infection |
2.0% |
| Folliculitis |
2.0% |
| Acne |
1.7% |
| Furuncle |
1.7% |
| Cardiovascular Event Prophylaxis |
1.3% |
| Cough |
1.3% |
| Influenza Like Illness |
1.3% |
| Nausea |
1.3% |
| Pneumocystis Jiroveci Pneumonia |
1.3% |
|
| Stevens-johnson Syndrome |
13.7% |
| Vomiting |
13.7% |
| Rash |
11.6% |
| Renal Failure Acute |
10.5% |
| Urticaria |
7.4% |
| Toxic Epidermal Necrolysis |
5.3% |
| Pyrexia |
4.2% |
| Thrombocytopenia |
3.7% |
| Drug Hypersensitivity |
3.2% |
| Pancreatitis |
3.2% |
| Rash Generalised |
3.2% |
| Swelling Face |
3.2% |
| Rash Maculo-papular |
2.6% |
| Rash Pruritic |
2.6% |
| Tremor |
2.6% |
| White Blood Cell Count Decreased |
2.6% |
| Hyperkalaemia |
2.1% |
| Blood Creatinine Increased |
1.6% |
| Erythema |
1.6% |
| Feeling Abnormal |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
30.7% |
| Drug Use For Unknown Indication |
22.6% |
| Hypertension |
7.4% |
| Hiv Infection |
6.7% |
| Prophylaxis |
5.3% |
| Lymphoma |
3.8% |
| Pyelonephritis |
2.7% |
| Urinary Tract Infection |
2.7% |
| Multiple Myeloma |
2.0% |
| Nausea |
1.9% |
| Immunosuppression |
1.8% |
| Essential Hypertension |
1.6% |
| Infection |
1.5% |
| Infection Prophylaxis |
1.5% |
| Anxiety |
1.4% |
| Glioblastoma Multiforme |
1.4% |
| Gastrointestinal Inflammation |
1.3% |
| Muscle Spasms |
1.2% |
| Staphylococcal Infection |
1.2% |
| Antifungal Prophylaxis |
1.1% |
|
| Renal Failure Acute |
11.2% |
| Renal Failure |
9.4% |
| Pyrexia |
8.2% |
| Thrombocytopenia |
7.1% |
| Vestibular Disorder |
6.5% |
| Vomiting |
5.9% |
| Rash Maculo-papular |
5.3% |
| Urticaria |
4.7% |
| Agranulocytosis |
4.1% |
| Drug Hypersensitivity |
4.1% |
| Henoch-schonlein Purpura |
4.1% |
| Oral Candidiasis |
4.1% |
| International Normalised Ratio Increased |
3.5% |
| Pharyngitis |
3.5% |
| Skin Exfoliation |
3.5% |
| Angioedema |
2.9% |
| Jaundice |
2.9% |
| Memory Impairment |
2.9% |
| Renal Tubular Disorder |
2.9% |
| Sepsis |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.7% |
| Drug Use For Unknown Indication |
14.4% |
| Hiv Infection |
12.3% |
| Multiple Myeloma |
7.0% |
| Prophylaxis |
6.4% |
| Pain |
4.4% |
| Hypertension |
3.8% |
| Depression |
3.1% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Nausea |
2.4% |
| Anxiety |
2.2% |
| Infection Prophylaxis |
2.0% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Renal Transplant |
1.8% |
| Prophylaxis Against Transplant Rejection |
1.8% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Urinary Tract Infection |
1.4% |
| Antifungal Prophylaxis |
1.4% |
| Insomnia |
1.3% |
| Acne |
1.3% |
|
| Vomiting |
15.2% |
| Thrombocytopenia |
9.0% |
| Weight Decreased |
7.9% |
| Renal Failure Acute |
7.8% |
| Pyrexia |
6.5% |
| Death |
6.4% |
| Pulmonary Embolism |
5.0% |
| White Blood Cell Count Decreased |
4.9% |
| Pneumonia |
4.6% |
| Urinary Tract Infection |
4.2% |
| Weight Increased |
3.9% |
| Respiratory Failure |
3.0% |
| Sepsis |
3.0% |
| Nausea |
2.9% |
| Tachycardia |
2.9% |
| Pain |
2.7% |
| Pancreatitis |
2.6% |
| Renal Failure |
2.6% |
| Septic Shock |
2.6% |
| Deep Vein Thrombosis |
2.4% |
|
| Interacting |
| Atrial Fibrillation |
14.6% |
| Anxiety |
7.3% |
| Depression |
7.3% |
| Lung Disorder |
7.3% |
| Erysipelas |
4.9% |
| Escherichia Sepsis |
4.9% |
| Insomnia |
4.9% |
| Lung Infection |
4.9% |
| Oral Candidiasis |
4.9% |
| Osteoporosis |
4.9% |
| Pulmonary Embolism |
4.9% |
| Sepsis |
4.9% |
| Type 1 Diabetes Mellitus |
4.9% |
| Urinary Tract Infection |
4.9% |
| Aspergilloma |
2.4% |
| Cellulitis Staphylococcal |
2.4% |
| Deep Vein Thrombosis |
2.4% |
| Hypertension |
2.4% |
| Non-hodgkin's Lymphoma |
2.4% |
| Renal Failure Chronic |
2.4% |
|
| International Normalised Ratio Increased |
18.2% |
| Oesophagitis Ulcerative |
18.2% |
| Renal Failure |
18.2% |
| Chills |
9.1% |
| Drug Interaction |
9.1% |
| Hyperkalaemia |
9.1% |
| Rhabdomyolysis |
9.1% |
| Vomiting |
9.1% |
|
